Fabio Girardi: The Omission of Anthracyclines for the Adjuvant Treatment of Women with TNBC
Fabio Girardi, Consultant Medical Oncologist at Veneto Oncology Institute IOV – IRCCS, shared a post on LinkedIn about a paper he co-authored with colleagues, published in The Breast:
“Risk-adapted treatment modulation is essential for preventing unnecessary long-term toxicities while ensuring a significant reduction of the risk of relapse.
Our meta-analysis of the omission of anthracyclines for the adjuvant treatment of women diagnosed with triple-negative breast cancer has been published in The Breast.
Anthracycline-free chemotherapy proved to be non-inferior to sequential adjuvant chemotherapy, with the strongest, pooled effect being observed for taxane-only regimens.
Non-inferiority was proved for the risk of recurrence, but not for the risk of death.
Our findings may be relevant to a low-risk population undergoing upfront surgery, but caution is needed given the heterogeneity of the studies.
Further research is warranted, with randomised trials or prospective observational studies aimed at robustly assessing the impact of omitting anthracyclines in a homogeneous, low-risk population of patients with early TNBC.
These studies should also incorporate a biomarker-driven stratification of the patient population using established prognostic factors such as tumour-infiltrating lymphocytes (TILs), to help identify patients to whom a treatment modulation can be safely offered.
The work is available Open Access.”
Title: Omitting anthracyclines for the adjuvant treatment of patients with triple-negative breast cancer: A non-inferiority meta-analysis
Authors: Fabio Girardi, Caterina Barbieri, Gaia Griguolo, Daniela Iannaccone, Christian Zurlo, Maria Vittoria Dieci, Valentina Guarneri.
You can read the Full Article in The Breast.
You can find more posts about TNBC in OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023